Prakash K Bhuyan (Prakash Bhuyan)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 7

Top Venues

Infectious diseases and therapy

Human vaccines & immunotherapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Norman Moullan, Josephat Asiago, Kathryn Stecco, Salah Hadi, Moetaz Albizem, Holly Tieu, Björn Hock, Craig Fenwick, Kai Lin, Thomas Lengsfeld, Lauren Poffenbarger, David Liu, Didier Trono, Giuseppe Pantaleo, Rajeev Venkayya, Prakash K Bhuyan
A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies. Infectious diseases and therapy 13 (1) (2024)
Norman Moullan, Josephat Asiago, Kathryn Stecco, Salah Hadi, Moetaz Albizem, Holly Tieu, Björn Hock, Craig Fenwick, Kai Lin, Thomas Lengsfeld, Lauren Poffenbarger, David Liu, Didier Trono, Giuseppe Pantaleo, Rajeev Venkayya, Prakash K Bhuyan
A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies. Infectious diseases and therapy 13 (1) (2024)
Norman Moullan, Josephat Asiago, Kathryn Stecco, Salah Hadi, Moetaz Albizem, Holly Tieu, Björn Hock, Craig Fenwick, Kai Lin, Thomas Lengsfeld, Lauren Poffenbarger, David Liu, Didier Trono, Giuseppe Pantaleo, Rajeev Venkayya, Prakash K Bhuyan
A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies. Infectious diseases and therapy (2024)
Norman Moullan, Josephat Asiago, Kathryn Stecco, Salah Hadi, Moetaz Albizem, Holly Tieu, Björn Hock, Craig Fenwick, Kai Lin, Thomas Lengsfeld, Lauren Poffenbarger, David Liu, Didier Trono, Giuseppe Pantaleo, Rajeev Venkayya, Prakash K Bhuyan
A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies. Infectious diseases and therapy 13 (1) (2024)
Norman Moullan, Josephat Asiago, Kathryn Stecco, Salah Hadi, Moetaz Albizem, Holly Tieu, Björn Hock, Craig Fenwick, Kai Lin, Thomas Lengsfeld, Lauren Poffenbarger, David Liu, Didier Trono, Giuseppe Pantaleo, Rajeev Venkayya, Prakash K Bhuyan
A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies. Infectious diseases and therapy 13 (1) (2024)
Prakash K Bhuyan, Michael Dallas, Kim Kraynyak, Timothy A Herring, Matthew Morrow, Jean Boyer, Susan Duff, Joseph Kim, David B Weiner
Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL. Human vaccines & immunotherapeutics 17 (5) (2020)
Rebecca K Hollenberg, Diane R Krieger, Robert Samuels, Kim Kraynyak, Albert J Sylvester, Matthew Morrow, Jean Boyer, Michael Dallas, Prakash K Bhuyan
Safety and immunogenicity of VGX-3100 formulations in a healthy young adult population. Human vaccines & immunotherapeutics 16 (6) (2019)

Prakash K Bhuyan.css-eqlu8i{font-size:small;padding-left:4px;} (Prakash Bhuyan)

Publication Activity (10 Years)

Top Topics

Top Venues

Prakash K Bhuyan (Prakash Bhuyan)